Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label Peptide Based Vaccine in Patients With Myeloproliferative Neoplasm Harboring CALR Mutations

NCT05025488 is registered in ClinicalTrials.gov with Marina Kremyanskaya as lead sponsor.

NCT NCT05025488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05025488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label Peptide Based Vaccine in Patients With Myeloproliferative Neoplasm Harboring CALR Mutations
Lead sponsor
Marina Kremyanskaya
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 4, 2023
Completion date
March 31, 2027
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia, mpn, myelofibrosis